RemAb Therapeutics

What RemAb Therapeutics does

RemAb Therapeutics is a preclinical-stage biopharmaceutical company founded in 2018 and headquartered at the Campus UAB research facility in Cerdanyola del Vallès, Barcelona, Spain. The company is built around its proprietary HART (Harmful Antibody Removal Technology) platform, a set of synthetic polymeric conjugates that selectively bind circulating pathogenic antibodies, forming immunocomplexes that are rapidly metabolised and excreted. HART is positioned as a horizontal platform: RemAb is developing five distinct therapeutic candidates on this scaffold, including RA0127 (anti-αGal antibody removal to protect ICU patients from Gram-negative bacterial infections and address antimicrobial resistance), RA0118 (anti-αGal IgE removal for tick-induced red meat allergy), RA02A/RA02B (anti-A/anti-B carbohydrate derivatives for ABO incompatibility in transfusions and transplants), RAAV03 (anti-AAV neutralizing antibody removal to broaden eligibility and enable redosing for gene therapy), and RA06GB (anti-TSHR antibody removal for Graves-Basedow disease).

The company is structured as a Spanish Sociedad Limitada (Remab Therapeutics sl.) with a 1–10 employee footprint and founder-led governance under CEO and co-founder Pablo Madrazo, President and CMO Dr. Rafael Máñez, CSO and co-founder Dr. Daniel Bello, and CCO Montserrat Tarrés Ferrán, supported by a Scientific Project Manager and technical staff. RemAb has no commercial products, no disclosed revenue, no disclosed pharmaceutical partnerships, and only a single disclosed capital infusion of $71,429 in seed funding from EISMEA and EIT Health in September 2018, suggesting capital has historically been sourced from non-dilutive European grants rather than venture financing. Its commercial model will, by standard biotech convention, depend on out-licensing, partnership, or co-development revenue once clinical-stage assets emerge, with a CCO hire hinting at early preparation for such transactions.

Name

RemAb Therapeutics

Legal name

Remab Therapeutics sl.

Website

https://remabtx.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

RemAb Therapeutics is a preclinical biopharmaceutical company developing the HART platform of synthetic polymeric conjugates that selectively remove harmful antibodies, with candidates targeting ICU bacterial infections, allergy, ABO blood-group incompatibility, gene therapy, and Graves-Basedow disease.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• Polymeric conjugates therapy
• Antibody removal technology
• Preclinical biotherapeutics
• Immunocomplex therapeutics
• Biopharmaceutical drug development

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Core offering

RemAb Therapeutics develops a proprietary platform of synthetic polymeric conjugates — the Harmful Antibody Removal Technology (HART) — that selectively bind to specific circulating harmful antibodies, forming immunocomplexes that are rapidly metabolized and excreted. The company is advancing a preclinical pipeline of therapeutic candidates targeting antibody-mediated conditions including Gram-negative bacterial infections in ICU patients, alpha-gal allergy, ABO blood-group incompatibility, anti-AAV neutralizing antibodies in gene therapy, and Graves-Basedow disease.

Product overview

RemAb Therapeutics is a biopharmaceutical company developing a platform of synthetic polymeric conjugates called HART (Harmful Antibody Removal Technology) for the selective intracorporeal removal of specific harmful antibodies. The core HART platform enables the development of multiple therapeutic candidates targeting different antibody-mediated conditions. The current product pipeline includes RA0127 for bacterial infections (ICU patients), RA0118 for allergies, RA02A/RA02B for blood group incompatibility, RAAV03 for gene therapy applications, and RA06GB for autoimmune diseases like Graves-Basedow disease.

Differentiator

Problem solved

Functional benefit

Products and services

• HART Platform (Harmful Antibody Removal Technology)

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves3 records

Expansion highlights4 records

Broad incumbents

• Pfizer: Major pharmaceutical company with approved AAV gene therapy (Beqvez) and active programs in gene therapy redosing strategies. Comparable as a large player addressing the anti-AAV NAb challenge that RAAV03 targets.
• Spark Therapeutics (Roche): Pioneer in AAV gene therapy (Luxturna) and broader gene therapy pipeline under Roche ownership. Comparable as a leader confronting anti-AAV NAb limitations that RAAV03 specifically addresses.
• Takeda Pharmaceutical: Large global pharmaceutical company with significant gene therapy (AAV-based) programs and immunology franchises. Comparable as a strategic acquirer/partner for RemAb's anti-AAV NAb (RAAV03) technology and broader antibody-removal applications.
• Hansoh Bio: Large Chinese biopharmaceutical company with growing innovative biologics pipeline. Comparable as a large player developing novel biologics including antibody-based therapeutics; potential partner for Asian market expansion.

Regional players

• Galapagos NV: European biotech (Belgium) developing novel therapeutics for immune-mediated and inflammatory diseases. Comparable as a European mid/large biotech focused on immunology indications overlapping with RemAb's autoimmune program.
• Innate Pharma: French clinical-stage biotech developing immunomodulatory therapeutics for cancer and inflammation. Comparable as a European immunology-focused biotech with similar stage and geographic positioning.

Direct peers

• Argenx: Clinical-stage Belgian biotech developing antibody-targeting therapeutics (e.g., FcRn antagonists like efgartigimod) for autoimmune diseases. Most directly comparable to RemAb in therapeutic focus on antibody-mediated conditions, though with a different mechanism (blocking antibody recycling vs. removing circulating antibodies).
• Cartesian Therapeutics: Clinical-stage biotech developing immunomodulation platforms (formerly Selecta Biosciences) including tolerogenic nanoparticles and cell therapies. Comparable as a platform-style biotech engineering immune responses, with similar stage profile.
• OSE Immunotherapeutics: French clinical-stage biotech developing immunomodulatory therapeutics for autoimmune and inflammatory diseases. Comparable as a European mid-stage immunology platform company with similar focus on modulating pathogenic immune responses.
• Immunovant: Clinical-stage biotech developing FcRn-targeting antibodies (batoclimab, IMVT-1402) for autoimmune diseases mediated by pathogenic antibodies. Highly comparable therapeutic area to RemAb's autoimmune program (RA06GB) and adjacent platform approach to antibody modulation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/RemAb_Tx

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RemAb Therapeutics